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South Africa (SA) has become one of the leading 
locations for the conduct of clinical trials due to its 
high-burden of disease, limited access to healthcare, 
well established research infrastructure and access 
to suitably qualified investigators.[1] Co-enrolment 
or concurrent enrolment of participants into multiple clinical trials 
testing therapeutic or prevention agents, is a potential risk in this 
setting.[2] Co-enrolment has the potential to affect the power of a 
study that determines the effect of an intervention, bias the study 
due to possible interactions between the interventions, increase the 
burden of clinic attendance and study procedures on participants and 
impact on the safety of the participant due to the possible unexpected 
interactions between interventions.[3] Reported reasons for co-
enrolment in this region include access to high quality healthcare 
at the clinical research site (CRS), study re-imbursements, altruism, 
access to investigational products such as study gels to enhance 
sexual pleasure, perceived low risk of being identified by researchers 
as being co-enrolled, and peer pressure by fellow co-enrollees.[3]
In 2008, the HIV Prevention Research Unit (HPRU) of the South 
African Medical Research Council (SAMRC) identified several 
participants who co-enrolled in two HIV prevention clinical trials being 
conducted in close proximity.[2] These co-enrolments fortunately did 
not impact on participant safety and study outcomes.[4] This incident 
did, however, raise concerns among sponsors and researchers that 
co-enrolment in HIV prevention clinical trials is a reality that must 
be identified and prevented from occurring.[4] When designing any 
research protocol, it is imperative that investigators consider the 
potential impact of co-enrolment on study outcomes, safety and 
burden of study procedures on participants. If co-enrolment has the 
potential to either augment or negate the therapeutic effect of the 
interventions or alter the adverse event profile of the intervention 
being studied, then the possibility of co-enrolment should be avoided. 
This consideration is especially important when implementing trials 
in resource-poor settings where trial participants are more likely to 
attempt to co-enrol.[2]
Biometrics co-enrolment prevention 
system
The biometrics co-enrolment prevention system (BCEPS) is a novel 
approach used to prevent co-enrolment of research parti cipants in multiple 
clinical trials in SA.[2] This system was developed and implemented by 
the HPRU in collaboration with the SAMRC Infor mation Technology (IT) 
Services Division and an external deve loper in 2010.[2] This is a web-
based system, which uses biometric technology to capture participant’s 
personal identification details in real time.[2] In brief, this system is used 
to  capture the participant’s full name, SA identity number or passport 
number (if not South African) and fingerprints. This information is used 
to determine if a participant has screened and/or enrolled at any other 
research site that is listed in the co-enrolment database. The system can 
also link studies which are pre-determined by the investigators, to allow 
co-enrolment.
BCEPS is currently utilised by 26 CRSs within 13 research orga-
nisa tions in SA, and to date has more than 26 500 participants 
registered on the system. All participating research organisations 
sign a memorandum of agreement (MOA) which is a legal 
agreement between the research organisation and SAMRC. On 
signing the MOA, the participating research organisations agree 
to abide by the terms and conditions applicable to the use of the 
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system. Prior to its implementation in 2010, BCEPS was externally 
evaluated by an independent company to ensure its functionality. 
More recently the system was audited by a study sponsor to verify 
compliance with applicable regulations and guidelines for the use 
of computerised systems in clinical trials and for compliance with 
the MOA.  
Regulatory oversight 
Research involving humans must be scientifically sound and 
conducted in accordance with basic ethical principles as outlined 
in the Declaration of Helsinki and by the Council for International 
Organisations of Medical Sciences (CIOMS): respect for persons, 
beneficence, and justice.[5,6] Furthermore, SA has stringent ethical 
guidelines stipulated by the National Health Act (2003) and the SA 
Good Clinical Practice (GCP) guidelines which ensure that the rights, 
wellbeing and safety of individuals participating in clinical trials are 
protected.[7,8] In addition, clinical research trials must be approved 
by the local ethics committee Medicines Control Council (MCC) and 
be registered with the South African National Health Research Ethic 
Committee (NHREC) trial registry. Registration of clinical trials on 
NHREC ensures that all SA researchers are aware of the current clinical 
trials being conducted.  
BCEPS was initially approved by the SAMRC ethics committee 
in 2010 for use in trials conducted within the HPRU and reviewed 
again in 2014. During the 2014 review process, the ethics committee 
commented that ‘the fingerprint system is good to have, but it should 
be balanced with ethics principles’. The following considerations were 
raised by the committee: 
• If the fingerprint database will be kept indefinitely, please pro vide 
more and detailed information on the safety and security mea-
sures that will be taken to preserve confidentiality. Who will be 
accountable for this sensitive information? The committee asked 
for guidelines and standard operating procedures (SOPs) for the 
use of fingerprints to give them assurance.
• Separate consent should be added to the informed consent where 
the participant agrees to give their fingerprints to other researchers.
• If a participant refuses to give their fingerprints, will they be 
exclu ded from the study? Can a participant ask to withdraw their 
fingerprint data from the database?
Based on the above mentioned findings, the following ethical 
considerations have been implemented:
Participant consent and rights 
To achieve understanding of BCEPS, participants are required to read 
and sign a co-enrolment participant information sheet (PIS), approved 
by the SAMRC ethics committee. This PIS includes comprehensive in-
for mation on the purpose and use of BCEPS. Participants also receive 
detailed counselling regarding the risks of co-enrolment at their 
screening, enrolment and at follow up clinic visits. The CRS staff must 
ensure that while consent is required to add the participant’s data 
to BCEPS, the participant does have a right to refuse, or to withdraw 
from BCEPS at any time. Investigator discretion is used to decide if it 
is safe for the participant to enrol in the study; or continue with study 
product use without co-enrolment checks if the participant refuses. 
To date, at HPRU, no participant has refused consent or withdrawn 
from BCEPS.
Participant confidentiality and privacy
When implementing BCEPS, care is taken to ensure the participants 
right to privacy and confidentiality is maintained as the system 
is used by many CRSs. The system is managed externally by the 
SAMRC IT Services Division, in order to preserve the confidentiality 
and security of participant data. This process is ex plained to partici-
pants in the waiting room. All SAMRC IT staff sign a confidentiality 
agreement. All correspondence regarding BCEPS queries is done via 
email between the participating CRSs and the SAMRC IT Services 
Division. It is therefore crucial that this communication does not 
compromise the confidentiality of the participants. Delegated CRS 
staff, trained to send queries to a dedicated email address, ensure 
that only essential participant information such as the name and 
SA identity number are shared. There is no link to the unique study 
identity number and any participant-specific study data. A copy of 
this correspondence is filed at the CRS and the email is deleted to 
ensure the protection of participant confidentiality. 
Data security and access  
To ensure that the system is secure and to prevent unauthorised 
access to the data, BCEPS is password protected and has two levels 
of authentication as a security measure. To gain access to the 
system authorised and trained study staff are required to login to a 
Secure Socket Layer Virtual Private Network (SSL VPN) portal using 
a username and password and thereafter login again using their 
fingerprint in order to access the application. The SSL VPN creates an 
encrypted connection between the user’s computer and the server. 
The BCEPS server hosting BCEPS is protected by a CISCO Systems Inc. 
firewall located in a demilitarised zone (DMZ). Fingerprints are stored 
as an encoded text string and not as an image and therefore cannot 
be copied or reverse engineered. No data, such as study identifiers 
or participant clinical data are stored locally, or on computers. 
When a participant is in attendance for a study visit at the CRS, their 
fingerprint is scanned to check if they are currently enrolled on the 
system. The system alerts the user if a co-enrolment is detected in 
another study or at another site. The researcher then has the option 
to contact the investigator from the other site and/or study to discuss 
the participant’s current status in the study in order to assess if it is 
safe to proceed with study participation. This process contributes to 
participant safety and data integrity. 
Data management and storage
Trained SAMRC IT staff members install BCEPS at each participating 
research site. They ensure that the delegated CRS staff are trained 
on the system and provided with a data entry guide that contains 
instructions on the use of BCEPS. Research staff then follow 
the site-specific standard operating procedures (SOPs) on the 
prevention of participant co-enrolment. 
Staff members who experience technical problems with BCEPS 
are encouraged to contact the SAMRC IT Ser vices Division that 
subsequently resolves all system related issues in a timeous 
manner. Data for each participant are maintained on the system 
for up to 15 years but can be removed by the SAMRC IT if 
requested by the participant. The data are backed up daily on the 
server and are also duplicated on the SAMRC disaster recovery site 
every night. Should internet connectivity be lost at site, there is an 
option to connect to the server using a dedicated laptop via 3G. 
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Quality assurance
Quality checks at the CRSs include verifying that the participant’s 
correct name and identity number, as per the SA identity document, 
has been captured. Daily checks are performed to ensure that no 
participant has inadvertently been omitted from BCEPS. If a parti-
cipant presenting at a research site is not captured on the system due 
to human error, this could have a huge impact on participant safety 
and data integrity. 
Conclusions and recommendations
Ethically, researchers must protect the rights, safety and wellbeing of 
participants. It is therefore important for each research organisation 
to develop a co-enrolment prevention plan or SOP which identifies 
all potential sources of co-enrolment and implements measures to 
prevent co-enrolment from occurring. To identify potential sources of 
co-enrolment, research organisations must engage with each other 
regularly as well as with all stakeholders and community structures 
to ensure that there is awareness of all investigational products 
undergoing clinical trials in the country. More importantly, CRSs 
within close geographical proximity must maintain open dialogue on 
their respective research agendas.  
Real-time verification of the enrolment status of participants 
using BCEPS is valuable to prevent co-enrolment. However, its 
utility is limited if all clinical research organisations conducting 
clini cal trials in SA do not subscribe to one co-enrolment prevention 
system. By addressing the ethical concerns around participant 
consent and rights, participant confidentiality and privacy, data 
security and access, and data management and storage, we were 
able to successfully implement BCEPS at HPRU. There have been no 
concerns raised by participants or communities regarding its use in 
our setting. 
Since SA will continue to conduct many large-scale trials, especially in 
the area of HIV prevention and treatment, it is essential that research 
organisations engage in robust dialogue on the potential ethical and 
safety concerns of co-enrolment and implement the use of a single 
shared database in the country to prevent co-enrolment in multiple 
studies. 
References
1. Wemos Foundation. The Clinical Trials Industry in South Africa: Ethics, Rules and 
Realities. Amsterdam: Wemos Foundation, 2013. http://www.wemos.nl/files/
Documenten%20Informatief/Bestanden%20voor%20’Medicijnen’/Clinical_
Trials_Industry_South_Africa_2013_v3.pdf (accessed 20 June 2014).
2. Harichund C, Haripersad K, Ramjee G. Participant verification: Prevention of 
co-enrolment in clinical trials in South Africa. S Afr Med J 2013;103(7):491-493. 
DOI:10.7196/SAMJ.6674
3. Karim QA, Kharsany A, Naidoo K, et al. Co-enrollment in multiple HIV prevention 
trials: Experiences from the CAPRISA 004 Tenofovir gel trial. J Contem Clin Trials 
2011;32(3):333-338. DOI:10.1016/j.ccc.2011.01.005
4. Ramjee G, Coumi N, Dladla-Qwabe N, et al. Experiences in conducting multiple 
community-based HIV prevention trials among women in KwaZulu-Natal, South 
Africa. AIDS Res Ther 2010;7:10. DOI:10.1186/1742-6405-7-10
5. World Medical Association. World Medical Association Declaration of Helsinki – 
Ethical Principles for Medical Research Involving Human Subjects. Paris: World 
Medical Association, 2013. http://www.wma.net/en/30publications/10policies/
b3/ (accessed 20 June 2014).
6. Council for International Organizations of Medical Sciences. International Ethical 
Guidelines for Biomedical Research Involving Human Subjects. Geneva: Council 
for International Organizations of Medical Sciences, 2002. http://www.cioms.ch/
publications/guidelines/guidelines_nov_2002_blurb.html. (accessed 20 June 2014).
7. Republic of South Africa. National Health Act. Pretoria: Government Gazette, 
2003. http://www.saflii.org/za/legis/consol_act/nha2003147/ (accessed 20 June 
2014).
8. Republic of South Africa, Department of Health. Guidelines for Good Practice in 
the Conduct of Clinical Trials with Human Participants in South Africa. Pretoria: 
Department of Health, 2006. http://www.google.co.za/url?sa=t&rct=j&q=&esrc=
s&source=web&cd=1&ved=0CBwQFjAA&url=http%3A%2F%2Fwww.kznhealth.
gov.za%2Fresearch%2Fguideline2.pdf&ei=FMO4VMiGCIeBPdWygcAK&usg=AF
QjCNFPS2z5fpitrvxT2v5_b4D-5k-BKg (accessed 20 June 2014).
